Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study (Q38411253)

2 September 2017

title

Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study (English)

1 reference

2 September 2017

1 reference

Partha S Ray

1

1 reference

2 September 2017

Sanjay P Bagaria

2

1 reference

2 September 2017

Jinhua Wang

3

1 reference

2 September 2017

Jaime M Shamonki

4

1 reference

2 September 2017

Xing Ye

5

1 reference

2 September 2017

Myung-Shin Sim

6

1 reference

2 September 2017

Shawn Steen

7

1 reference

2 September 2017

Ying Qu

8

1 reference

2 September 2017

Xiaojiang Cui

9

1 reference

2 September 2017

Armando E Giuliano

10

1 reference

2 September 2017

publication date

18 March 2011

1 reference

Annals of Surgical Oncology

2 September 2017

published in

1 reference

2 September 2017

volume

18

1 reference

2 September 2017

issue

13

1 reference

2 September 2017

page(s)

3839-3847

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-011-1657-8

2 September 2017

exact match

0 references

cites work

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Are triple-negative tumours and basal-like breast cancer synonymous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Are triple-negative and basal-like breast cancer synonymous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Treatment and survival outcome for molecular breast cancer subtypes in black women

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Subtypes of breast cancer show preferential site of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

REporting recommendations for tumour MARKer prognostic studies (REMARK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

Survival probabilities (the Kaplan-Meier method).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

A new look at the statistical model identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-1657-8

10.1245/S10434-011-1657-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1005758521

0 references

1 reference